AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain. The company was formerly known as SuRx Pharmaceuticals, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood City, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ACRX
CUSIPN/A
Phone650-216-3500
Debt
Debt-to-Equity Ratio-0.20
Current Ratio4.05
Quick Ratio4.00
Price-To-Earnings
Trailing P/E Ratio-2.68
Forward P/E Ratio-3.73
P/E GrowthN/A
Sales & Book Value
Annual Sales$7.99 million
Price / Sales18.95
Cash FlowN/A
Price / CashN/A
Book Value($0.73) per share
Price / Book-4.04
Profitability
EPS (Most Recent Fiscal Year)($1.10)
Net Income$-51,500,000.00
Net Margins-909.33%
Return on EquityN/A
Return on Assets-62.92%
Miscellaneous
Employees41
Outstanding Shares51,320,000
Market Cap$151.40
AcelRx Pharmaceuticals (NASDAQ:ACRX) Frequently Asked Questions
What is AcelRx Pharmaceuticals' stock symbol?
AcelRx Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACRX."
How were AcelRx Pharmaceuticals' earnings last quarter?
AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) announced its earnings results on Wednesday, May, 9th. The specialty pharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.01. The specialty pharmaceutical company had revenue of $0.34 million for the quarter, compared to analysts' expectations of $0.78 million. View AcelRx Pharmaceuticals' Earnings History.
When is AcelRx Pharmaceuticals' next earnings date?
What price target have analysts set for ACRX?
9 analysts have issued twelve-month price objectives for AcelRx Pharmaceuticals' stock. Their predictions range from $2.00 to $8.00. On average, they expect AcelRx Pharmaceuticals' share price to reach $5.20 in the next twelve months. This suggests a possible upside of 76.3% from the stock's current price. View Analyst Ratings for AcelRx Pharmaceuticals.
What is the consensus analysts' recommendation for AcelRx Pharmaceuticals?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AcelRx Pharmaceuticals in the last year. There are currently 4 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
Who are some of AcelRx Pharmaceuticals' key competitors?
Some companies that are related to AcelRx Pharmaceuticals include TIGENIX/S (TIG), ChemoCentryx (CCXI), Five Prime Therapeutics (FPRX), Obseva (OBSV), Geron (GERN), Prothena (PRTA), Theratechnologies (THERF), Akebia Therapeutics (AKBA), Beyondspring (BYSI), Aduro BioTech (ADRO), CannTrust (CNTTF), Keryx Biopharmaceuticals (KERX), Merus (MRUS), Arcus Biosciences (RCUS) and Depomed (DEPO).
Who are AcelRx Pharmaceuticals' key executives?
AcelRx Pharmaceuticals' management team includes the folowing people:
- Dr. Pamela Pierce Palmer, Co-Founder, Chief Medical Officer & Director (Age 55)
- Ms. Jane Wright-Mitchell, Chief Legal Officer (Age 49)
- Mr. Lawrence G. Hamel, Chief Devel. Officer (Age 66)
- Mr. Anil N. Dasu, Chief Engineering Officer (Age 55)
- Mr. Vincent J. Angotti, CEO & Director (Age 50)
Has AcelRx Pharmaceuticals been receiving favorable news coverage?
Media coverage about ACRX stock has trended somewhat positive recently, Accern reports. The research firm ranks the sentiment of news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. AcelRx Pharmaceuticals earned a media sentiment score of 0.06 on Accern's scale. They also assigned press coverage about the specialty pharmaceutical company an impact score of 49.15 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.
Who are AcelRx Pharmaceuticals' major shareholders?
AcelRx Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include LEERINK REVELATION HEALTHCARE FUND I, L.P. (7.30%) and INDUSTRY VENTURES SECONDARY VIII, L.P. (7.30%). Company insiders that own AcelRx Pharmaceuticals stock include Lawrence G Hamel, Life Sciences Maste Perceptive, Mark G Edwards, Pamela P Palmer, Perceptive Advisors Llc, Raffi Asadorian and Vincent J Angotti. View Institutional Ownership Trends for AcelRx Pharmaceuticals.
How do I buy shares of AcelRx Pharmaceuticals?
Shares of ACRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is AcelRx Pharmaceuticals' stock price today?
One share of ACRX stock can currently be purchased for approximately $2.95.
How big of a company is AcelRx Pharmaceuticals?
AcelRx Pharmaceuticals has a market capitalization of $151.40 million and generates $7.99 million in revenue each year. The specialty pharmaceutical company earns $-51,500,000.00 in net income (profit) each year or ($1.10) on an earnings per share basis. AcelRx Pharmaceuticals employs 41 workers across the globe.
How can I contact AcelRx Pharmaceuticals?
AcelRx Pharmaceuticals' mailing address is 351 GALVESTON DRIVE, REDWOOD CITY CA, 94063. The specialty pharmaceutical company can be reached via phone at 650-216-3500 or via email at [email protected]
MarketBeat Community Rating for AcelRx Pharmaceuticals (NASDAQ ACRX)
MarketBeat's community ratings are surveys of what our community members think about AcelRx Pharmaceuticals and other stocks. Vote "Outperform" if you believe ACRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
